Rheumatoid arthritis is a common chronic disease, and healthcare companies are increasingly eager to develop agents with the potential to treat the causes of the condition. As discussed in this feature, the considerable level of innovation and inter-company collaboration this requires is evident from an overview of recent rheumatoid arthritis deals.